![Lopinavir–ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial - The Lancet Lopinavir–ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial - The Lancet](https://www.thelancet.com/cms/attachment/b9733e70-68a2-473a-8618-32f0f5a0590c/gr1_lrg.gif)
Lopinavir–ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial - The Lancet
![AbbVie's HIV drug Kaletra stumbles in COVID-19 trial, but one analyst begs to differ | Fierce Pharma AbbVie's HIV drug Kaletra stumbles in COVID-19 trial, but one analyst begs to differ | Fierce Pharma](https://qtxasset.com/quartz/qcloud5/media/image/fiercepharma/1584625962/CoronaBugOnline.jpg/CoronaBugOnline.jpg?VersionId=Z.M57RATA4iD7w1WZ614GWU5d7.cYc76)
AbbVie's HIV drug Kaletra stumbles in COVID-19 trial, but one analyst begs to differ | Fierce Pharma
![An overview of the safety assessment of medicines currently used in the COVID-19 disease treatment - ScienceDirect An overview of the safety assessment of medicines currently used in the COVID-19 disease treatment - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0278691520305299-fx1.jpg)
An overview of the safety assessment of medicines currently used in the COVID-19 disease treatment - ScienceDirect
Why Are Lopinavir and Ritonavir Effective against the Newly Emerged Coronavirus 2019? Atomistic Insights into the Inhibitory Mechanisms | Biochemistry
![Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled phase III trial - The Lancet Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled phase III trial - The Lancet](https://www.thelancet.com/cms/attachment/2000989824/2003645882/gr1.gif)
Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled phase III trial - The Lancet
![Lopinavir/ritonavir: A rapid review of effectiveness in COVID-19 - The Centre for Evidence-Based Medicine Lopinavir/ritonavir: A rapid review of effectiveness in COVID-19 - The Centre for Evidence-Based Medicine](https://www.cebm.net/wp-content/uploads/2020/04/lopinavir.jpg)
Lopinavir/ritonavir: A rapid review of effectiveness in COVID-19 - The Centre for Evidence-Based Medicine
![Lopinavir/ritonavir, a new galenic oral formulation from commercial solid form, fine-tuned by nuclear magnetic resonance spectroscopy | European Journal of Hospital Pharmacy Lopinavir/ritonavir, a new galenic oral formulation from commercial solid form, fine-tuned by nuclear magnetic resonance spectroscopy | European Journal of Hospital Pharmacy](https://ejhp.bmj.com/content/ejhpharm/29/5/259/F1.large.jpg)
Lopinavir/ritonavir, a new galenic oral formulation from commercial solid form, fine-tuned by nuclear magnetic resonance spectroscopy | European Journal of Hospital Pharmacy
![These highlights do not include all the information needed to use KALETRA safely and effectively. See full prescribing information for KALETRA. KALETRA (lopinavir and ritonavir) tablet, for oral use KALETRA (lopinavir and These highlights do not include all the information needed to use KALETRA safely and effectively. See full prescribing information for KALETRA. KALETRA (lopinavir and ritonavir) tablet, for oral use KALETRA (lopinavir and](https://dailymed.nlm.nih.gov/dailymed/image.cfm?name=kaletra-tablets-and-oral-solution-spl-04.jpg&id=718339)
These highlights do not include all the information needed to use KALETRA safely and effectively. See full prescribing information for KALETRA. KALETRA (lopinavir and ritonavir) tablet, for oral use KALETRA (lopinavir and
![TropicalMed | Free Full-Text | Efficacy and Safety of Lopinavir/Ritonavir for Treatment of COVID-19: A Systematic Review and Meta-Analysis TropicalMed | Free Full-Text | Efficacy and Safety of Lopinavir/Ritonavir for Treatment of COVID-19: A Systematic Review and Meta-Analysis](https://www.mdpi.com/tropicalmed/tropicalmed-05-00180/article_deploy/html/images/tropicalmed-05-00180-g013.png)
TropicalMed | Free Full-Text | Efficacy and Safety of Lopinavir/Ritonavir for Treatment of COVID-19: A Systematic Review and Meta-Analysis
![Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study - The ... Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study - The ...](https://www.thelancet.com/cms/attachment/2000996624/2003695796/gr1.gif)